Antiviral Drugs - Central Africa

Central Africa

The Antiviral Drugs market in Central Africa is projected to witness a substantial increase in revenue, with an estimated value of US$20.77m by 2024.
This projection indicates a positive growth trend for the market in the coming years.
Furthermore, the market is expected to exhibit an annual growth rate of 1.59% between 2024 and 2029, ultimately reaching a market volume of US$22.47m by 2029.
When compared globally, it is worth noting that United States is anticipated to generate the highest revenue in the Antiviral Drugs market, with an estimated value of US$30,640.00m in 2024.
This showcases the significant market potential and dominance of the United States in this particular market.
Central Africa is experiencing a surge in demand for antiviral drugs due to the increasing prevalence of infectious diseases in the region.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Antiviral Drugs in Central Africa has been steadily increasing in recent years.

Customer preferences: Customers in Central Africa are increasingly seeking out antiviral drugs due to the rise in infectious diseases such as HIV/AIDS, Ebola, and COVID-19. The need for effective treatments has become a top priority for both healthcare providers and patients.

Trends in the market: There has been a noticeable increase in the production and distribution of generic antiviral drugs in Central Africa. This has led to a decrease in prices and an increase in accessibility for patients. Additionally, there has been a shift towards combination therapies, which offer a more comprehensive treatment approach.

Local special circumstances: Central Africa has a high prevalence of infectious diseases, which has driven the demand for antiviral drugs. Additionally, the region has a relatively low level of healthcare infrastructure and resources, which can make it difficult for patients to access the care they need. This has led to a growing need for affordable and effective treatments.

Underlying macroeconomic factors: The political and economic instability in Central Africa has made it difficult for pharmaceutical companies to operate in the region. However, there has been a recent push by governments and international organizations to increase access to healthcare and improve the overall health outcomes in the region. This has created opportunities for pharmaceutical companies to expand their operations and meet the growing demand for antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.